Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 97,983	$ 150,456
Short-term marketable securities	271,985	265,198
Accounts receivable	1,056	4,846
Prepaid expenses and other current assets	7,199	4,004
Total current assets	378,223	424,504
Long-term marketable securities	17,179	15,391
Property and equipment, net	25,931	3,986
Goodwill	8,164	8,469
Intangible assets, net	29,805	29,400
Restricted cash	468
Other assets	7,216	75
Total assets	466,986	481,825
Current liabilities:
Accounts payable	1,908	5,086
Accrued clinical trial and manufacturing expenses	7,283	5,522
Accrued expenses and other liabilities	9,678	5,412
Deferred revenue	15,164	15,046
Total current liabilities	34,033	31,066
Deferred rent	5,937
Contingent consideration	3,542	3,750
Deferred revenue	166,667	178,037
Deferred tax liabilities	6,868	7,350
Total liabilities	217,047	220,203
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2016 and December 31, 2015; and zero shares issued and outstanding at September 30, 2016 and December 31, 2015
Common stock, $0.0001 par value; 300,000,000 shares authorized September 30, 2016 and December 31, 2015; and 67,114,020 and 63,587,833 shares issued and outstanding at September 30, 2016 and December 31, 2015	7	6
Additional paid-in capital	411,516	362,807
Accumulated other comprehensive income (loss)	850	(339)
Accumulated deficit	(162,434)	(100,852)
Total stockholders’ equity	249,939	261,622
Total liabilities and stockholders’ equity	$ 466,986	$ 481,825